Kazia Therapeutics halted with news pending on accelerated entitlement offer

Kazia Therapeutics Ltd (ASX:KZA) has been granted a trading halt ahead of an announcement relating to the outcome of the institutional component of an accelerated non-renounceable entitlement offer.

The halt will remain in place until the beginning of regular ASX trading on Friday, October 2, or when an announcement is released to the market, whichever occurs earliest.

Collaboration with Dana-Farber Cancer Institute

Kazia is collaborating with Dana-Farber Cancer Institute (DFCI) in the US to investigate the use of Kazia’s investigational new drug paxalisib (formerly GDC-0084) in primary central nervous system lymphoma (PCNSL).

DFCI will initiate an open-label phase II clinical trial of paxalisib in PCNSL and this study is expected to recruit up to 25 patients, taking up to two years to complete.

This study will be the sixth ongoing clinical trial of paxalisib in brain cancer and Kazia will provide support including study drug and a financial grant.

Dana Farber Cancer Institute will launch a single-arm phase II clinical trial in patients with relapsed or refractory PCNSL, who are resistant to existing treatments.

The primary endpoint will be to assess efficacy via overall response rate (ORR), which measures the ability of paxalisib to shrink tumours.

Safety and other efficacy endpoints will also be captured.

Story by ProactiveInvestors